- Home
- CLLS vs SOPH Comparison
CLLS vs SOPH Comparison
Compare CLLS & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- SOPH
- Stock Information
- Founded
- CLLS 1999
- SOPH 2011
- Country
- CLLS France
- SOPH Switzerland
- Employees
- CLLS N/A
- SOPH N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLLS Health Care
- SOPH Health Care
- Exchange
- CLLS Nasdaq
- SOPH Nasdaq
- Market Cap
- CLLS 299.0M
- SOPH 231.8M
- IPO Year
- CLLS 2007
- SOPH 2021
- Fundamental
- Price
- CLLS $3.08
- SOPH $3.23
- Analyst Decision
- CLLS Buy
- SOPH
- Analyst Count
- CLLS 1
- SOPH 0
- Target Price
- CLLS $4.00
- SOPH N/A
- AVG Volume (30 Days)
- CLLS 71.4K
- SOPH 38.8K
- Earning Date
- CLLS 11-03-2025
- SOPH 11-04-2025
- Dividend Yield
- CLLS N/A
- SOPH N/A
- EPS Growth
- CLLS N/A
- SOPH N/A
- EPS
- CLLS N/A
- SOPH N/A
- Revenue
- CLLS $63,438,000.00
- SOPH $69,688,000.00
- Revenue This Year
- CLLS N/A
- SOPH $16.60
- Revenue Next Year
- CLLS $66.76
- SOPH $18.77
- P/E Ratio
- CLLS N/A
- SOPH N/A
- Revenue Growth
- CLLS 223.09
- SOPH 7.32
- 52 Week Low
- CLLS $1.10
- SOPH $2.58
- 52 Week High
- CLLS $3.35
- SOPH $4.92
- Technical
- Relative Strength Index (RSI)
- CLLS 62.30
- SOPH 46.63
- Support Level
- CLLS $2.88
- SOPH $3.10
- Resistance Level
- CLLS $3.20
- SOPH $3.49
- Average True Range (ATR)
- CLLS 0.17
- SOPH 0.16
- MACD
- CLLS 0.02
- SOPH -0.02
- Stochastic Oscillator
- CLLS 68.24
- SOPH 31.71
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.